In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atlas Genetics Ready To Play Its Part In The POC Workflow Revolution

Executive Summary

Do it once, do it right and do it quick: when it comes to diagnostic testing, that suits patients and payer systems that are pursuing budget-sensitive, quality-driven health care solutions. It could also be the shorthand mission statement of POC diagnostics developer Atlas Genetics, which is developing a new IVD platform technology for infectious disease tests.

You may also be interested in...



Atlas Genetics Fundraising Pulls In New Chinese Investment

Atlas Genetics, a UK point-of-care molecular diagnostics developer, has raised $35m in Series D financing from an investor syndicate. The funding round attracted existing shareholders and new investment from Chinese in vitro diagnostic company Wondfo Biotech.

Atlas First In Market With 30-Minute POC Molecular Test For Chlamydia

Atlas Genetics is bringing to market the first point-of-care molecular diagnostic test for chlamydia that can deliver results in 30 minutes. The rapid turnaround time will hopefully reduce the number of patients who do not go back to retrieve their results and consequently not get the necessary treatment should they have the sexually transmitted infection (STI).

Biosecurity Centre And ‘Test And Trace’ To Augment UK’s COVID-19 Test Momentum

The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1131839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel